Relmada Therapeutics Market Sentiment

Market sentiment signals for Relmada Therapeutics (RLMD): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▲ 12.8% short float

Options Flow▲ 0.00 P/C ratio

Insider Activity— N/A

Analyst Consensus

Buy

9 analysts

Options Flow (P/C)

0.00

More calls — Bullish

2 calls · 0 puts

Avg Consensus PT

$10

+119.3%

Highest Price Target

$19

+316.7%

Mizuho

Lowest Price Target

-78.1%

Leerink Partners

Short Interest

12.8%

Declining — Bullish

Insider Activity (30d)

—

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Jun 18, 2026	HC Wainwright & Co.	Andres Y. Maldonado—	+163.2%	$12	Initiate	Buy
Mar 24, 2026	Piper Sandler	Kelsey Goodwin—	+163.2%	$12	Initiate	Overweight
Mar 20, 2026	Mizuho	Uy Ear—	+316.7%	$10 → $19	Maintained	Outperform
Mar 2, 2026	LUCID CAPITAL MARKETS	Christopher Liu—	+207.0%	$14	Initiate	Buy
Jan 23, 2026	Leerink Partners	Andrew Berens—	+75.4%	$8	Upgrade	Market Perform→Outperform
Dec 22, 2025	Jefferies	Farzin Haque—	+97.4%	$9	Initiate	Buy
Nov 19, 2025	Mizuho	Uy Ear—	+119.3%	$1 → $10	Upgrade	Neutral→Outperform
Dec 5, 2024	Mizuho	Uy Ear—	-78.1%	$23 → $1	Downgrade	Outperform→Neutral
Dec 4, 2024	Leerink Partners	Marc Goodman—	-78.1%	$10 → $1	Downgrade	Outperform→Market Perform
Sep 17, 2024	Jefferies	Andrew Tsai—	+185.1%	$4 → $13	Upgrade	Hold→Buy
Jun 5, 2024	Goldman Sachs	Andrea Tan—	-56.1%	$3 → $2	Downgrade	Neutral→Sell

More with Benzinga EdgeGet Access

Insider & Market Activity News

PRO
Relmada Therapeutics Form4 Filing Shows CEO Sergio Traversa Bought 1,225,500 Shares At An Average Price Of $0.09/Share

- SEC Filing

Benzinga Newsdesk

PRO
Relmada Therapeutics CMO Raj S. Pruthi Purchases 55,000 Shares In Open Market On August 29, 2025

On August 29, 2025, Raj S. Pruthi, MD, Chief Medical Officer-Urology of Relmada Therapeutics, Inc. (the "Company"), purchased in open market transactions 55,000 shares of the Company's common stock, $0.001 par value per

Benzinga Newsdesk

Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying

The Dow Jones index closed lower by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Avi Kapoor

Relmada Therapeutics CEO Sergio Traversa Reported Purchase Of 100,000 Shares @ Avg Price Of $3.87/Share In Form 4 Filing On Wednesday

Charles Gross

Chief Financial Officer at Relmada Therapeutics Acquires Company Stock Options Worth 317,643 Shares

Benzinga Insights

Relmada Therapeutics Chief Executive Officer Awarded $1.53M Worth of Stock Options

Benzinga Insights

Relmada Therapeutics Inc